Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium - Part 2

Schwierz C, Thiry N, Van de Sande S, Gamil M, Nevens F, Colle I, Horsmans Y, Hulstaert F
Record ID 32010001403
Dutch, English, French
Authors' objectives:

This is the second report of the KCE project on health-economic aspects of antiviral treatment of chronic hepatitis B (CHB). The overall goal of the project is the study of the cost-effectiveness of the recently introduced antiviral drugs in Belgium (tenofovir and entecavir), using a model based as much as possible on Belgian data. These Belgian data allow ascertaining to a better degree the quality of our results and the possibility of drawing policy recommendations. As lamivudine is no longer considered a state-of-theart first line treatment of CHB, as adefovir is a second line treatment, as (pegylated) interferon-alpha is an appropriate first line treatment for selected patients only, we use the natural history as comparator.

In this second part, we add to the natural history literature the preliminary results on disease progression by patient age based on a large untreated cohort of Caucasian patients followed at Leuven University Hospital. We compare and complement our measured utility scores with a review of the literature on health utilities for different CHB disease states. We analyse and report Belgian HBV-related healthcare consumption data by CHB disease state.
Details
Project Status: Completed
URL for project: https://kce.fgov.be/publication/report/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium
Year Published: 2011
URL for published report: https://kce.fgov.be/publication/report/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Belgium
MeSH Terms
  • Antiviral Agents
  • Cost-Benefit Analysis
  • Hepatitis B, Chronic
  • Interferon-alpha
  • Tenofovir
Contact
Organisation Name: Belgian Health Care Knowledge Centre
Contact Address: Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85
Contact Name: info@kce.fgov.be
Contact Email: info@kce.fgov.be
Copyright: <p>Belgian Health Care Knowledge Centre (KCE)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.